BeiGene Touts Topline Phase 3 Data for Nasopharyngeal Cancer Therapy

Chinese drugmaker BeiGene said its anti-PD-1 antibody tislelizumab combined with chemotherapy improved survival for patients with recurrent or metastatic nasopharyngeal cancer in a late-stage trial.

In the 263-participant phase 3 trial, tislelizumab plus chemotherapy was shown to be more effective than chemotherapy alone for improving progression-free survival, the company said.

Tislelizumab is already approved in China for treating advanced squamous nonsmall-cell lung cancer in combination with chemotherapy and conditionally approved for patients with Hodgkin’s lymphoma and metastatic bladder cancer with high PD-L1 expression.